89bio To Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

(Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announcedthat Rohan Palekar, the companys Chief Executive Officer, will participate in 1x1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020.

Metadata

Provider:

GlobeNewswire, Inc.

Retrieved on:

Tuesday, November 24, 2020

Information

Tags:

Inotek Pharmaceuticals

Geotags:

San Francisco, Us

Organisation:

89BIO, INC.

Summary

Key Points:

(Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announcedthat Rohan Palekar, the companys Chief Executive Officer, will participate in 1x1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020.
The conference will take place December 1-3, 2020.
An archived webcast of the fireside chat is accessible in the investor section of 89bios website .
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases.

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Rohan Palekar, the company’s Chief Executive Officer, will participate in 1x1 meetings with investors at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020. The conference will take place December 1-3, 2020. An archived webcast of the fireside chat is accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
[email protected]

Media Contact:
Peter Duckler
773-343-3069
[email protected]